Wolfram Syndrome Panel
Use
This test is intended for individuals with clinical or suspected diagnosis of Wolfram syndrome, particularly those with symptom onset before age 15. It involves sequencing two genes known to be associated with Wolfram syndrome. This test can assist in confirming a diagnosis and guiding patient management.
Special Instructions
Not provided.
Limitations
The test is limited to the identification of pathogenic variants in the specified genes associated with Wolfram syndrome. It may not detect all mutations involved in this condition, especially in non-coding regions or genes not included in the panel. The test is not cleared by the FDA but follows CAP and CLIA regulations.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided